Literature DB >> 6831475

Phase II evaluation of anguidine in central nervous system tumors: a southwest Oncology Group study.

J W Goodwin, R H Bottomley, C B Vaughn, J Frank, R P Pugh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6831475

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

Review 2.  Toward a Cancer Drug of Fungal Origin.

Authors:  Alexander Kornienko; Antonio Evidente; Maurizio Vurro; Véronique Mathieu; Alessio Cimmino; Marco Evidente; Willem A L van Otterlo; Ramesh Dasari; Florence Lefranc; Robert Kiss
Journal:  Med Res Rev       Date:  2015-04-08       Impact factor: 12.944

Review 3.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Anguidine potentiates cis-platinum in human brain tumor cells.

Authors:  R A Hromas; W K Yung
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.